Tag: Bioxyne Limited
Bioxyne signs $5.6M supply agreement to enter German medical cannabis market
Bioxyne Limited), through its subsidiary Breathe Life Sciences (BLS), has entered the German medical cannabis market by securing a commercial supply agreement worth a minimum of €3.2 million (approximately AUD 5.6 million) for FY2026.
Bioxyne granted Australia’s first GMP licence for Psilocybin and MDMA manufacturing
Bioxyne Limited's subsidiary, Breathe Life Sciences (BLS), has secured the Good Manufacturing Practice (GMP) licence for the production of medical cannabis.
Featured Article
Don’t get left behind: Manufacturing’s urgent need for digital transformation
As digital transformation reshapes industries worldwide, manufacturers in Australia and beyond are finding themselves at the forefront of an evolution. This shift presents opportunities for companies looking to improve efficiency, drive innovation, and boost growth.
